ABIOMED

History

Year	Detail
1981	Abiomed was founded to develop the first artificial heart in the U.S.
1992	Company's BVS 5000 becomes the first ventricular assist device ever U.S. FDA-approved for bridge-to-recovery.
2001	Abiomed physicians treat the first AbioCor patient with the first totally implantable artificial heart.
2005	It has acquired Impella CardioSystems in Aachen, Germany.
2008	The company has completed the PROTECT I clinical trial, and its Impella 2.5 heart pump has received U.S. FDA 510(k) clearance.
2009	AB Portable Driver receives U.S. FDA approval and the first patient is discharged on AB5000.
2011	Launched the New Automated Impella Controller (AIC).
2012	Abiomed cofounds MedTechVets to help military veterans find jobs in the medical device industry.
2013	It has started the RECOVER RIGHT clinical trial in the U.S. for the Impella RP heart pump.
2014	Abiomed announces the acquisition of ECP, a medical device company based in Berlin, Germany.
2016	The Impella 2.5 and Impella 5.0 heart pumps receive regulatory approval in Japan.
2017	Opened its newly-expanded headquarters in Danvers, Massachusetts, and Abiomed Physicians treated the first patient with Impella in Japan.
2018	Abiomed launched the Women's Initiative for Heart Recovery, and it has received regulatory approval for the SmartAssist technology.
2020	The company has acquired Breethe and its OXY-1 System and treats first patients with ECMO technology above left.
2021	U.S. FDA grants the highest level of approval to the Impella RP with SmartAssist for right heart failure and it has acquired preCARDIA to improve outcomes for heart failure patients.
2022	Johnson & Johnson has acquired Abiomed and the same year it was delisted from the NASDAQ.